Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 430  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
CORRESPONDENCE
Year : 2009  |  Volume : 54  |  Issue : 1  |  Page : 88-89
The efficacy of topical diphencyprone in the treatment of alopecia areata


Department of Dermatology, Razi Hospital, Tehran University of Medical, Sciences, Tehran, Iran

Correspondence Address:
Lajevardi Vahide
Department of Dermatology, Razi Hospital, Tehran University of Medical, Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.49001

Rights and Permissions



How to cite this article:
Maryam A, Hassan S, Farshad F, Parastoo B, Vahide L. The efficacy of topical diphencyprone in the treatment of alopecia areata. Indian J Dermatol 2009;54:88-9

How to cite this URL:
Maryam A, Hassan S, Farshad F, Parastoo B, Vahide L. The efficacy of topical diphencyprone in the treatment of alopecia areata. Indian J Dermatol [serial online] 2009 [cited 2019 Jun 16];54:88-9. Available from: http://www.e-ijd.org/text.asp?2009/54/1/88/49001


Sir,

In a retrospective study, 54 patients (38 females and 16 males) with chronic extensive alopecia areata, who had used diphencyprone (DPCP) for more than 1.5 years, between January of 2001 and December of 2005, were studied. The extent of hair loss was severe (>75%), moderate (26-75%), and mild (<25%) in 68.5%, 29.6%, and 1.9% of them, respectively. The mean duration of the disease was 7.8 8.1 years.

The patients were sensitized initially with a 2% solution of DPCP in acetone, which was applied to a 5-centimeter-diameter circular area on the scalp. Treatment started two weeks after sensitization with 0.001% DPCP, on one-half of the patient's scalp. The concentration of the solution used was increased stepwise (0.01%, 0.1%, 0.2%, 0.5%, 1% and 2%) until redness, pruritus, but without vesicular eruption maintained. The patients were instructed to avoid direct exposure of the scalp to sun and not to wash the scalp for 48 hours after DPCP treatment. If terminal hair growth was noted, the entire scalp was treated under the same weekly protocol.

Terminal hair regrowth on the scalp was excellent (76-100%) in 40.7%, good (51-75%) in 14.8%, moderate (26-50%) in 14.8%, and mild (<25%) in 29.6% of patients [Figure 1],[Figure 2],[Figure 3].

Sixty two percent of the patients, with a duration of ≤10 years, had good and/or excellent response to the treatment ( P = 0.017).

There was no relationship between response to treatment and sex, onset of disease, nail involvement, atopy, extent of hair loss, and family history of alopecia areata.

During the treatment, 33% of the patients experienced relapse. Continuation of the DPCP therapy caused hair re-growth in 21 of them. Adverse effects included contact dermatitis on the face or neck (five of 54), hyperpigmentation (four of 54) and occipital lymphadenopathy (one of 54).

In this study, the response to the treatment in 55.5% of the patients was appropriate. In other reports, however, the percentage of success varied greatly from four to 85%. [1] The changes in response rates may be due to the number of patients in trials, the type, duration and severity of the alopecia areata, and different methods of assessing clinical efficacy.

In addition, in our study, duration of disease was the only predictor for response rate. The presence of nail changes, a personal history of atopy, long duration of alopecia before treatment, baseline extent of alopecia, age at disease onset and duration of treatment have been considered as prognostic factors in other studies. [2],[3],[4]

It seems that the topical DPCP in the treatment of severe alopecia areata is effective, but with a slightly high relapse rate during treatment. Duration of the disease, less than 10 years, is a main predictor for this response rate.

 
   References Top

1.Happle R. Diphencyprone for the treatment of alopecia areata: More data and new aspects. Arch Dermatol 2002;138:112-3.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Firooz A, Bouzari N, Mojtahed F, Pazoki-Toroudi H, Nassiri-Kashani M, Davoudi M, et al . Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata. J Eur Acad Dermatol Venereol 2005;19:393-4.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Galadari I, Rubaie S, Alkaabi J, Galadari H. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 2003;35:397-401.  Back to cited text no. 3  [PUBMED]  
4.Singh G, Okade R, Naik C, Dayanand CD. Diphencyprone immunotherapy in ophiasis. Indian J Dermatol Venerol Leprol 2007;73:432-3.  Back to cited text no. 4    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
Print this article  Email this article
 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (322 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Figures

 Article Access Statistics
    Viewed6735    
    Printed100    
    Emailed1    
    PDF Downloaded278    
    Comments [Add]    

Recommend this journal